SNCA and Parkinson disease: Recently, reducing α-synuclein level has gained attention as a therapeutic method to limit the progression of PD [12]; however, experimental evidence on the long-term effects of removing α-synuclein on the development and normal function of the autonomic nervous system is lacking.